These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34504786)

  • 1. A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment.
    Pilanc P; Wojnicki K; Roura AJ; Cyranowski S; Ellert-Miklaszewska A; Ochocka N; Gielniewski B; Grzybowski MM; Błaszczyk R; Stańczak PS; Dobrzański P; Kaminska B
    Front Oncol; 2021; 11():703465. PubMed ID: 34504786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
    Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
    J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
    Aaboe Jørgensen M; Ugel S; Linder Hübbe M; Carretta M; Perez-Penco M; Weis-Banke SE; Martinenaite E; Kopp K; Chapellier M; Adamo A; De Sanctis F; Frusteri C; Iezzi M; Zocca MB; Hargbøll Madsen D; Wakatsuki Pedersen A; Bronte V; Andersen MH
    Cancer Immunol Res; 2021 Nov; 9(11):1316-1326. PubMed ID: 34518197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Arginase Expression in Glioma-Associated Microglia and Macrophages.
    Zhang I; Alizadeh D; Liang J; Zhang L; Gao H; Song Y; Ren H; Ouyang M; Wu X; D'Apuzzo M; Badie B
    PLoS One; 2016; 11(12):e0165118. PubMed ID: 27936099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma.
    Sosnowska A; Chlebowska-Tuz J; Matryba P; Pilch Z; Greig A; Wolny A; Grzywa TM; Rydzynska Z; Sokolowska O; Rygiel TP; Grzybowski M; Stanczak P; Blaszczyk R; Nowis D; Golab J
    Oncoimmunology; 2021; 10(1):1956143. PubMed ID: 34367736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.
    Gieryng A; Pszczolkowska D; Bocian K; Dabrowski M; Rajan WD; Kloss M; Mieczkowski J; Kaminska B
    Sci Rep; 2017 Dec; 7(1):17556. PubMed ID: 29242629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginase 1 is a key driver of immune suppression in pancreatic cancer.
    Menjivar RE; Nwosu ZC; Du W; Donahue KL; Hong HS; Espinoza C; Brown K; Velez-Delgado A; Yan W; Lima F; Bischoff A; Kadiyala P; Salas-Escabillas D; Crawford HC; Bednar F; Carpenter E; Zhang Y; Halbrook CJ; Lyssiotis CA; Pasca di Magliano M
    Elife; 2023 Feb; 12():. PubMed ID: 36727849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.
    Miret JJ; Kirschmeier P; Koyama S; Zhu M; Li YY; Naito Y; Wu M; Malladi VS; Huang W; Walker W; Palakurthi S; Dranoff G; Hammerman PS; Pecot CV; Wong KK; Akbay EA
    J Immunother Cancer; 2019 Feb; 7(1):32. PubMed ID: 30728077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
    Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
    JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment.
    Su X; Xu Y; Fox GC; Xiang J; Kwakwa KA; Davis JL; Belle JI; Lee WC; Wong WH; Fontana F; Hernandez-Aya LF; Kobayashi T; Tomasson HM; Su J; Bakewell SJ; Stewart SA; Egbulefu C; Karmakar P; Meyer MA; Veis DJ; DeNardo DG; Lanza GM; Achilefu S; Weilbaecher KN
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34520398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer.
    Grzybowski MM; Stańczak PS; Pomper P; Błaszczyk R; Borek B; Gzik A; Nowicka J; Jędrzejczak K; Brzezińska J; Rejczak T; Güner-Chalimoniuk NC; Kikulska A; Mlącki M; Pęczkowicz-Szyszka J; Olczak J; Gołębiowski A; Dzwonek K; Dobrzański P; Zasłona Z
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
    Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
    Hasan MN; Luo L; Ding D; Song S; Bhuiyan MIH; Liu R; Foley LM; Guan X; Kohanbash G; Hitchens TK; Castro MG; Zhang Z; Sun D
    Theranostics; 2021; 11(3):1295-1309. PubMed ID: 33391535
    [No Abstract]   [Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity.
    Ramji K; Grzywa TM; Sosnowska A; Paterek A; Okninska M; Pilch Z; Barankiewicz J; Garbicz F; Borg K; Bany-Laszewicz U; Zerrouqi A; Pyrzynska B; Rodziewicz-Lurzynska A; Papiernik D; Sklepkiewicz P; Kedzierska H; Staruch A; Sadowski R; Ciepiela O; Lech-Maranda E; Juszczynski P; Mackiewicz U; Maczewski M; Nowis D; Golab J
    Sci Rep; 2022 Nov; 12(1):19660. PubMed ID: 36385153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.